Clinical Trials Browser

Phase 2/3 × Adenocarcinoma × camrelizumab × Clear all

NCT04208347 2026-01-23

Perioperative Treatment of Combined SOX With Apatinib and Camrelizumab for Oesophagogastric Cancer

Phase 2/3 Active not recruiting

Adenocarcinoma